Skip to main content
Genexine, Inc. logo

Genexine, Inc. — Investor Relations & Filings

Ticker · 095700 ISIN · KR7095700001 KO Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2025-03-10 Audit Report / Informat…
Country KR South Korea
Listing KO 095700

About Genexine, Inc.

http://www.genexine.com/

Genexine, Inc. is a clinical-stage biotechnology company focused on developing and commercializing immunotherapeutics and next-generation biologics. The company utilizes its proprietary hyFc® platform technology to create long-acting protein therapeutics. Its pipeline is led by GX-I7, a long-acting interleukin-7 designed to amplify T-cell counts for immuno-oncology applications. Other key assets in late-stage clinical trials include GX-E4, a long-acting treatment for anemia, and GX-H9 for growth hormone deficiency. Genexine's research and development efforts primarily target oncology and rare diseases.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) system titled '감사보고서 제출' (Submission of Audit Report). It provides the audit opinion (unqualified/proper), key financial data, and auditor information for the fiscal year. While it contains financial data, it is a standard regulatory disclosure announcement regarding the receipt and submission of the audit report, rather than the full annual report document itself. Therefore, it fits the 'Audit Report / Information' category as it specifically reports the audit results and opinion. FY 2024
2025-03-10 Korean
사업보고서 (2024.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'Genexine' (주식회사 제넥신) for the fiscal year ending December 31, 2024. It includes the independent auditor's opinion, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and notes. This is a comprehensive financial audit document, not an earnings release or a simple announcement, and it fits the definition of an Audit Report (AR). FY 2024
2025-03-10 Korean
투자판단관련주요경영사항(임상시험결과) (재발성 교모세포종 환자에서 베바시주맙 (bevacizumab)과 GX-I7 병용투여의 유효성 및 안전성을 확인하기 위한 공개형, 단일군 제2상 임상시험 결과)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory disclosure from a Korean company (Genexine) regarding the results of a Phase 2 clinical trial. It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) filed with the Korea Exchange (KRX). Since it details specific clinical trial outcomes, efficacy data, and safety results, it falls under the category of regulatory filings that provide material information to investors, which is best classified as a Regulatory Filing (RNS) in this taxonomy.
2025-02-26 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Genexine) regarding a significant change in revenue or profit structure (30% or more). This is a standard disclosure requirement for companies listed on the KOSDAQ exchange when financial results deviate significantly from the previous period. It provides a summary table of financial performance and the reasons for the change, which is characteristic of an Earnings Release (ER) or a mandatory regulatory disclosure of financial results. FY 2024
2025-02-06 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (DART system) used when an individual or entity's shareholding in a listed company crosses a specific threshold (typically 5%). The document details the shareholding changes of Sung Young Chul in Genexine, including the number of shares held, the reason for the change (loan repayment, resignation of an executive), and the list of special related parties. This falls under the category of Major Shareholding Notification.
2025-01-20 Korean
기타시장안내 (연구개발 우수기업 매출액 특례적용 관련)
Regulatory Filings Classification · 100% confidence The document is a short regulatory notice from Genexine regarding the fulfillment of specific KOSDAQ market listing requirements related to R&D excellence and revenue exemptions. It does not constitute a full financial report, proxy, or other specific category, but rather serves as a formal regulatory announcement to the market. Given its nature as a miscellaneous regulatory update, it falls under the RNS category.
2025-01-07 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.